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We describe the Pancreatic Expression Database (PED), the first cancer database originally designed based on the BioMart
infrastructure. The PED portal brings together multidimensional pancreatic cancer data from the literature including
genomic, proteomic, miRNA and gene expression profiles. Based on the BioMart 0.7 framework, the database is easily
integrated with other BioMart-compliant resources, such as Ensembl and Reactome, to give access to a wide range of
annotations alongside detailed experimental conditions. This article is intended to give an overview of PED, describe its
data content and work through examples of how to successfully mine and integrate pancreatic cancer data sets and other
BioMart resources.
Database URL: http://www.pancreasexpression.org
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Project description
In cancer research, advances in technology have resulted in
the generation of vast quantities of complex data. Barriers
to the effective use of this data include heterogeneity and
lack of interoperability between isolated resources (1). We
attempted to overcome these obstacles to cancer research
by using BioMart (2) to design a generic model for a com-
prehensive cancer resource. Initially, focusing our efforts on
pancreatic cancer, we established the Pancreatic Expression
Database (PED) (3–5).
PED is a major resource for the integration and mining of
pancreatic cancer literature data. With its data content con-
stantly growing, PED contains the largest collection of pan-
creatic cancer molecular profiling data sets. Currently, the
database includes over 60 000 measurements obtained
using a range of omics technologies; including transcrip-
tomics, proteomics, genomics and miRNA. The expansion
in data content improved query capabilities and enhanced
interoperability have facilitated the systematic study of
pancreatic cancer. Although a number of expression data
repositories and literature databases exist, PED provides a
unique way to integrate and mine data specifically related
to pancreatic cancer and cross-query data from other
biomart databases and, therefore, allows the community
to perform highly detailed queries on facets of pancreatic
cancer.
The PED system comprises of tools capable of querying
data content either by using simple queries based on an
individual premise such as gene expression, or by combin-
ing information across multiple data types such as conduct-
ing a query addressing both gene expression and copy
number data (Figures 1 and 2). By providing the capacity
to refine any biological data query according to various
criteria, PED provides a resource that allows the pancreatic
cancer community to explore and find new relation-
ships among the factors that contribute to the pathogen-
esis of this disease. The resulting information can be
used to elucidate the changes associated with tumouri-
genesis and the development of resistance to treatment
and aid in the development of novel molecular diagnostic
tools for the prevention and diagnosis of pancreatic
cancer.
As with all BioMarts, multiple access levels are provided
by PED to ensure universal appeal to all members of
the research community. The database is freely access-
ible through a BioMart web-based query interface
at: www.pancreasexpression.org. To ensure maximal
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that it can be used in other resources or browsers such as
Ensembl (7). Provision of a data link alerting EntrezGene (8)
users of relevant genes in PED is also accessible as a Linkout
resource. Moreover, programmatic access is possible
through third-party software tools such as R/BioConductor
(9), Galaxy (10) and Cytoscape (11). Most importantly, PED is
interoperable with the International Cancer Genome
Consortium (ICGC) (12), a large-scale collaboration aimed
at examining somatically acquired transcriptomic and epi-
genetic alterations in 50 globally important tumour types
or subtypes including pancreatic cancer. The ICGC
data portal includes PED annotations on its gene report
pages (13).
Figure 1. Schematic representation of the querying process for the PED CNV data sets. (A) Filters and (B) Attributes.
.............................................................................................................................................................................................................................................................................................
Page 2 of 6
Original article Database, Vol. 2011, Article ID bar024, doi:10.1093/database/bar024
.............................................................................................................................................................................................................................................................................................Figure 2. Schematic representation of the querying process for the PED expression data set. (A) Filters and (B) Attributes.
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The database describes the association of over 6000 DNA
copy number alterations; 8000 genes and their 30 000 tran-
scripts and 22 000 proteins; and 279 miRNAs in pancreatic
cancer as well as the observed levels of deregulation
among a broad range of specimen and experimental
types (Table 1). These include healthy/patient tissues and
body fluids specimens, cell lines and murine models as well
as the provision of information pertaining to any treat-
ments/drugs administered to the samples during the
study.
Query examples
PED allows the user to combine complex queries to ask de-
tailed disease-specific questions and combine results with
public annotation sources. There are options available for
genomics, proteomics, transcriptomics and miRNA profil-
ing, allowing these data types to be queried in isolation
or combined (Figures 1 and 2). The interface incorporates
the full functionality and data from Ensembl and BioMart
for cross-linking different data sets.
To demonstrate the utility of PED, we present several
biologically relevant queries that can be performed using
the current system.
Query 1: Find genes commonly deregulated in pancreatic
cancer precursor lesions, pancreatic intraepithelial neo-
plasia (PanIN) samples and display gene information,
comparison and direction of regulation.
Data set Filters Attributes
Pancreatic
Expression
Database
Specimen: HGNC symbol
PanIN-1b: only Ensembl Gene Id
PanIN-1b/2: only Ensembl Transcript ID
PanIN-2: only Comparison
PanIN-3: only Direction of regulation
Predictive biomarkers are vital to cancer research and
have been shown to enhance long-term survival for many
solid tumours. This data are vital in the identification of
asymptomatic, early-stage disease biomarkers. This is espe-
cially true for pancreatic cancer, one of the most lethal of
solid tumours in which patients tend to be diagnosed in
advanced stages of the disease (14).
It is well-established and widely accepted that
pancreatic adenocarcinoma (PDAC) progresses from non-
invasive pancreatic lesions—pancreatic intraepithelial neo-
plasia (PanINs) (15). Based on the degree of cellular and
nuclear atypia, these precursor neoplasia are delineated
as PanIN-1a, PanIN-1b, PanIN-2 and PanIN-3.
The results retrieved in response to Query 1 display genes
that have been expressed in all the PanIN collection
included in the database. The results table will also provide
links to the original studies. In this instance, the deregula-
tion of the S100P gene is highlighted as an early event in
the development of pancreatic cancer. This is in accordance
with previous published findings (16,17).
Query 2: Find genes differentially expressed in the
serum of pancreatic cancer patients when compared to
the serum of patients with benign pancreatic diseases
(chronic pancreatitis and pancreatic pseudocyst).
Find associated pathways via query integration with
Reactome. Display gene and protein information, experi-
mental details and pathway information.
Data sets Filters Attributes
Pancreatic
Expression
Database
Comparison: HGNC symbol
Pancreatic cancer versus
benign pancreatic disease
(CP and pancreatic
pseudocyst) (serum)
Ensembl Gene Id
Limit output to: pancreatic
cancer patients/benign
pancreatic disease (chronic
pancreatitis and pancreatic
pseudocyst) (serum)
Ensembl Protein ID
Comparison
Direction of
Regulation
Fold change
Platform
Reactome
[pathway]
Species: Homo sapiens Pathway name
Pathway DB ID
Determination of reliable non-invasive biomarkers, such
as those present in serum, are important when attempting
to avoid surgical intervention and limit any physiological
and psychological stress on the patient. PED not only
allows users to query profiles derived from tissues but
also those from media such as serum, plasma and urine.
In addition, linking of the PED resource to Reactome (18)
Table 1. Overview of the current PED data content
Data content
Transcripts 30324
Proteins 22336
Genes 8229
miRNA 279
Genomic copy number alterations: gains
and amplifications
4068
Genomic copy number alterations: losses
and deletions
1420
Genomic copy number alterations: loss of
heterozygosity
875
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to pancreatic cancer for biomarker discovery and visualiza-
tion of the affected pathways.
Query 3: Find DNA copy number high-level amplifications
in PDAC samples that also contain genes differentially
expressed in PDAC versus chronic pancreatitis (CP) and
display copy number information, gene information and
differential expression experimental details (Figure 1).
Data set Filters Attributes
Copy number
variations
(pancreatic
cancer)
Specimen/cell type: pancreatic
adenocarcinoma (PDAC): only
Chromosome
Copy number information:
high-level amplification: only
Start
Pancreatic expression com-
parisons: pancreatic adenocar-
cinoma (PDAC) versus chronic
pancreatitis (CP) (microdis-
sected): only
End
Ensembl Gene ID
Pancreatic
expression
comparison
The query above shows a simple way to integrate
multi-dimensional data by combining data on copy
number variations with results from differential expression.
This will give an overview of genomic or transcriptomic
changes of any chromosome(s) or chromosomal region(s)
in the selected sample(s) as determined by a variety of plat-
forms stored in PED. By overlaying the information on tran-
scriptional deregulation from expression arrays and gene
content with copy number variations from genomic
arrays, one can quickly highlight the commonly affected
regions in the studied patient population and the impact
of the copy number aberrations on gene expression pat-
terns. For example, by looking for high-level amplifications
and genes up-regulated in PDAC when compared to chronic
pancreatitis, it is possible to highlight potential oncogenes.
Query 4: Find miRNAs differentially expressed in PDAC
versus CP whose expression has been confirmed by
RT–PCR techniques and display miRNA attributes and
study information (Figure 2).
Data set Filters Attributes
Pancreatic
Expression
Database
Gene:
Gene type: miRNA
miRNA Profiling:
Platform: qRT-PCR
Comparison: PDAC
versus CP (microdissected)
Ensembl Gene Id
miRBase ID(s)
miRBase Accession(s)
Study
Comparison
Direction of
regulation
miRNAs bind to target sites in the 30-UTR region of
mRNA and act as repressors of protein-coding genes
or activators of RNA degradation. Aberrant expression
of miRNAs involved in pancreatic cancer can be easily
retrieved from PED.
Discussion and future directions
PED has become well-established in the pancreatic cancer
community as a key resource for mining relevant literature
information. Recent updates have added in different infor-
mation types including copy number variations from pan-
creatic cancer samples and other expression experiments
such as proteomics and miRNA.
The successful development and implementation of PED
fills the urgent requirement of the pancreatic cancer com-
munity for resources capable of integrating the overflow-
ing influx of data generated by novel high-throughput
technologies.
The architectural flexibility of PED BioMart-based
schema means that it can be easily extended to encompass
additional malignant and non-malignant diseases and has
been used as a prototype for other malignant diseases such
as breast cancer (http://bioinformatics.breastcancertissue-
bank.org).
The use of BioMart as a framework facilitates interoper-
ability with other cancer resources and enables users to
cross-query data from a number of relevant resources
rather than being limited to a single database. The
International Cancer Genome Consortium uses BioMart
technology to share data and make it publicly available.
Data from PED is automatically cross-queried from the
ICGC (see ICGC paper in this issue) and can be queried with
COSMIC data (19) via the BioMart framework. This allows
direct cross-comparison of experimental findings generated
from the two ICGC pancreatic cancer projects (Australia and
Canada) with literature-derived information from PED.
Plans for the database include expanding to include rea-
nalysed differential expression data and methods to enable
users to assess the quality of the information added to the
database. There are also plans to improve the graphical
data view, especially for genomic information.
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